Aim To evaluate the clinical, demographic, and molecular genetic characteristics of patients with homozygous familial hypercholesterolemia (HoFH), as well as the effectiveness of lipid-lowering therapy and the incidence of cardiovascular complications, based on the RENAISSANCE registry (Registry of patiENts with FH and very high cArdIovaScular riSk pAtients with iNuffiCient rEsponse to lipid-lowering therapy). Material and methods The RENAISSANCE registry is an open-label, national observational study involving patients with FH. The diagnosis of HoFH was established according to the 2014 European Atherosclerosis Society criteria. The study accounted for atherosclerosis risk factors, physical examination findings, cardiovascular history, and current lipid-lowering therapy. Lipid profile parameters included concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a). Most patients underwent genetic testing for hypercholesterolemia. The study's endpoint comprised fatal and non-fatal cardiovascular events. Results The study included 6 children and 13 adults (6 males) with HoFH. The mean age was 26±14 years; an average follow-up period in the registry was 5.3±2.8 years. Tendon xanthomas were observed in 68% of patients, cutaneous xanthomas in 74%, and corneal arcus in 47%. The mean age of cardiovascular disease onset was 22 ± 8 years. Ischemic heart disease was diagnosed in 63% of patients, and 47% had undergone cardiovascular interventions (arterial revascularization, aortic valve replacement). The mortality rate reached 21%. Peak LDL-C level was 17.7±4.0 mmol/L. By the final visit, LDL-C had decreased by 46% to 9.6±5.6 mmol/L, though only four patients (21%) achieved an LDL-C level ≤3 mmol/L. The median lipoprotein(a) concentration was 100 [27; 145] mg/dL, with elevated levels (≥30 mg/dL) identified in 10 patients (67%). Treatment regimens included statins (95%), ezetimibe (95%), PCSK9 inhibitors (37%), and lomitapide (21%); 53% of patients underwent lipoprotein apheresis. During the follow-up period, 14 cardiovascular events occurred across 7 patients (including one child): 4 coronary artery bypass grafts, 6 aortic valve replacements, and 4 deaths. Conclusion In the registry-based observational study of patients with HoFH, there was an increase in the use of complex combination therapies, including lipoprotein apheresis and lomitapide. However, reaching target LDL-C levels remains challenging, and the incidence of cardiovascular complications remains high.